Rachel Hurley

Employment

• University of Pennsylvania Instructor
  2026 - Present
• Children's Hospital of Philadelphia Fellow Physician, Division of Oncology
  2022 - 2026

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (25)

• TIME to Target Sarcomas: Lessons from the Tumor Immune Microenvironment
  Annual Review of Pathology: Mechanisms of Disease 2026 DOI: 10.1146/annurev-pathmechdis-042624-121246
  +Save
• Abstract C021: Characterization of a Novel Inducible Mouse Model of Synovial Sarcoma
  Cancer Research 2026 DOI: 10.1158/1538-7445.pediatric26-c021
  +Save
• BCLXL blockade rewires cell fate to overcome PARP inhibitor resistance in ovarian cancer.
  Signal transduction and targeted therapy 2026 DOI: 10.1038/s41392-026-02870-7
  +Save
• Characterization and validation of a methylation signature as a prognostic marker in osteosarcoma.
  Journal of Clinical Oncology 2026 DOI: 10.1200/jco.2026.44.16_suppl.10016
  +Save
• Sustained Response to Trametinib in Central Giant Cell Granuloma With KRAS Gain-of-Function Mutation: A Case Report
  JCO Precision Oncology 2026 DOI: 10.1200/PO-26-00247
  +Save
• Infantile Fibrosarcoma of the Hand: Limb-Sparing Treatment With Modern Targeted Oral Chemotherapy and Conservative Surgical Resection.
  Journal of hand surgery global online 2025 DOI: 10.1016/j.jhsg.2025.100887
  +Save
• Codon specific readthrough as a mechanism of BRCA2 restoration in acquired PARP inhibitor and chemotherapy resistance.
  Nucleic acids research 2025 DOI: 10.1093/nar/gkaf990
  +Save
• Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivity.
  Experimental hematology & oncology 2025 DOI: 10.1186/s40164-025-00681-0
  +Save
• Solid Tumors
  Nelson Pediatrics Board Review 2025
  +Save
• CINSARC score use in pediatric non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) in the Children’s Oncology Group (COG) studies ARST0332 and ARST1321.
  Journal of Clinical Oncology 2024 DOI: 10.1200/jco.2024.42.16_suppl.10013
  +Save
• A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.
  Cancer chemotherapy and pharmacology 2022 DOI: 10.1007/s00280-022-04430-6
  +Save
• CHFR and Paclitaxel Sensitivity of Ovarian Cancer.
  Cancers 2021 DOI: 10.3390/cancers13236043
  +Save
• Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma.
  Ksenija Nesic, Olga Kondrashova, Rachel M. Hurley +28 more
  Cancer research 2021 DOI: 10.1158/0008-5472.can-21-0774
  +Save
• Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance.
  NAR cancer 2021 DOI: 10.1093/narcan/zcab028
  +Save
• Hereditary Thrombotic Thrombocytopenic Purpura in a 9-Month-old: Diagnosing and Managing an Ultra-rare Disorder.
  Journal of pediatric hematology/oncology 2021 DOI: 10.1097/mph.0000000000001830
  +Save
• Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting.
  Scientific reports 2021 DOI: 10.1038/s41598-021-87470-x
  +Save
• Poly (ADP-Ribose) Polymerase Inhibition for Chemotherapy-Induced Peripheral Neuropathy: A Meta-Analysis of Placebo-Controlled Trials.
  Journal of palliative medicine 2019 DOI: 10.1089/jpm.2018.0572
  +Save
• 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
  Gynecologic oncology 2019 DOI: 10.1016/j.ygyno.2019.01.015
  +Save
• In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
  Gynecologic oncology 2016 DOI: 10.1016/j.ygyno.2016.08.328
  +Save
• Targeting Pancreatic Cancer Metastasis by Inhibition of Vav1, a Driver of Tumor Cell Invasion.
  Cancer research 2015 DOI: 10.1158/0008-5472.can-14-3103
  +Save